UTHR CEO Rothblatt: $38M Exercise-and-Sell Across 7 Sessions

United Therapeutics Chairperson & CEO Martine Rothblatt has been executing a textbook exercise-and-sell cadence on United Therapeutics (UTHR) across seven trading sessions from April 16 through May 7, 2026. Each session: exercise 9,500 options at a $146.03 strike (Form 4 code M), then sell exactly 9,500 shares at the open market between $585 and $597 per share (code S). Aggregate proceeds across the seven sessions clear roughly $38M; the embedded intrinsic value from the option exercise (price minus strike, times shares) accounts for ~$29M of that. The pattern is mechanically uniform, executed under what is structurally a Rule 10b5-1 plan, and is materially different from a discretionary CEO sell.

The cadence is the entire story. Discretionary CEO sales do not happen in 9,500-share increments seven sessions running, each preceded by an option exercise at the same strike. The exercise-then-sell sequence — where an in-the-money option is converted to common stock and the common is sold the same day at market — is the standard plan structure used by long-tenured executives to convert option compensation into liquidity in a tax- and disclosure-compliant manner. Rothblatt's career trading profile shows similar exercise-and-sell sequences across multiple prior years, with the per-session sizing adjusting as her plan rolls forward.

The Seven-Session Cadence

Daily aggregate from Form 4 filings, with proceeds calculated from the per-share execution prices in the line items. Each session also included an M (option exercise) of 9,500 shares at $146.03 strike, generating the underlying common stock sold in the same day's S transactions:

Note the 8-19 fill profile per session: each session's S parent order is sliced across an intraday VWAP-style execution, which is the operational signature of an algorithmic plan broker. A discretionary block sale runs 1-3 fills, not 8-19. The May 7 session's higher fill count likely reflects a slightly wider market spread that day.

What the Form 4 Table I Balance Says

Per the most recent filing, Rothblatt directly held 34,288 shares of UTHR after the May 7 transactions. That balance reflects the position remaining after the exercise-and-sell sequence concludes the parent option block — not her total beneficial ownership. The Form 4 Table I balance is the directly-held common stock; long-tenured biotech CEOs typically hold additional positions through family trusts, charitable foundations, and unvested option grants that don't surface on Table I until exercise. The 13D/G beneficial-ownership tape shows United Therapeutics' own Schedule 13G filings tracking the percentage threshold around 4-7% across recent years.

The Institutional Holder Layer

The other 13D/G data points worth noting: Vanguard Capital Management filed a 13G on April 30, 2026 reporting 5.190% beneficial ownership (2,278,348 shares), and Wellington Management Group filed a Schedule 13G in February 2026 reporting 5.700% (2,441,492 shares). The Wellington filing is the more interesting institutional data point — Wellington runs an active asset management book, and a fresh 13G crossing the 5% threshold typically reflects accumulation rather than passive index drift. Vanguard's 13G is the standard passive overlay.

Why an Exercise-and-Sell Pattern Matters

The single biggest editorial error in coverage of long-tenured biotech CEO sales is conflating an exercise-and-sell sequence with a discretionary directional view. Three structural reasons the cadence is not bearish:

• Option expiration management: Options have finite expiration windows. An executive whose options are approaching expiration must exercise to capture intrinsic value, regardless of any view on the stock's forward path.
• Tax-management timing: Spreading exercises across multiple tax years and within Rule 10b5-1 plan windows is the standard CFO/tax-counsel recommendation for executives holding deep-in-the-money options. The 9,500-share-per-session sizing is almost certainly indexed to a plan with annual exercise targets.
• Compensation conversion: The exercise converts a compensation grant (the option) into liquid common stock, then the sell converts the common stock to cash. Each step is a structural finance step, not a directional bet.

For the pattern to read as bearish, the cadence would need to deviate — a sudden block sale outside the plan window, a discretionary sale at the open of trading (S without preceding M), or coordination with other senior officers showing similar timing. None of those signals appear in the Rothblatt Form 4 tape across the seven sessions.

UTHR Earnings Context

United Therapeutics' lead franchise — Tyvaso DPI / nebulized treprostinil for pulmonary arterial hypertension — continues to drive the revenue base, with the company's pipeline now expanding into pulmonary fibrosis indications (Tyvaso IPF) and the longer-tail xenotransplantation effort through Lung Biotechnology. The exercise-and-sell pattern is uncorrelated with any of those clinical readouts; it pre-dates the recent Tyvaso IPF momentum and continues regardless of analyst price-target moves. The cadence will most likely pause inside the next earnings blackout window, which is the standard 10b5-1 plan suspend-and-resume behavior.

The Anchors to Watch

• UTHR Q2 2026 earnings: typically late-July / early-August window. The plan pauses inside the blackout; resumption with new cadence parameters would signal a refresh.
• 10b5-1 plan refresh: plans are typically refreshed annually. A change in share count per session (away from the 9,500 baseline) is the rule-change to watch.
• Wellington 13G/A refresh: Wellington's February 2026 13G is the most recent 5%+ institutional filing — any amendment would update the active-manager position read.
• Senior officer Form 4 tape: if the CFO or other C-suite officers initiate parallel exercise-and-sell sequences in the next 30 days, that would shift the coordination read.

The headline-friendly framing — 'CEO sells $38M in 3 weeks' — is technically accurate on the dollar amount and misleading on the implication. The Rothblatt Form 4 tape is a textbook exercise-and-sell sequence executed under a 10b5-1 plan; the directional sentiment read is muted. See Rothblatt's full insider trading history →

For broader context on biotech CEO compensation structures and how exercise-and-sell sequences differ from discretionary blocks, the learn library covers Form 4 transaction codes and the 10b5-1 plan framework. Cross-stock confluence in biotech insider activity surfaces in the smart-money signal feed.